mEpoR Knockout/Tg(hEpoR) Mouse Model for Anemia and Renal Function Studies

Description:
mEpoR-/- hEpoR+: The mouse Erythropoietin Receptor knockout that contains a human Erythropoietin Receptor transgene can be used to define the potency of recombinant erythropoietin preparations used to treat anemia associated with chronic kidney disease.

Erythropoietin, acting by binding to Erythropoietin receptors (EpoR) on erythroid progenitor cells, is required for erythropoiesis. Absence of erythropoietin or the EpoR in mice interrupts erythropoiesis in the fetal liver and result in death at embryonic day 13.5. An 80-kb human EpoR transgene bred onto a mouse EpoR null background (provided by F. Constantini of Columbia University) restored effective erythropoiesis in the EpoR null mouse. Erythropoietin preparations made utilizing recombinant DNA technology are used in the treatment of anemia in chronic kidney disease and other critical illnesses. The mouse EpoR null mouse containing the human EpoR transgene can be used to define the potency of erythropoietin preparation in humans.
Patent Information:
For Information, Contact:
Betty Tong
Technology Licensing Specialist
NIH Technology Transfer
301-451-7836
tongb@niddk.nih.gov
Inventors:
Constance Noguchi
Keywords:
ACXXXX
AXXXXX
EPO
EpoR
Erythropoietin
ICXXXX
IDXXXX
IXXXXX
Mice
RECEPTOR
© 2024. All Rights Reserved. Powered by Inteum